|  | 2020 | 2021 | 2022 |
| --- | --- | --- | --- |
|  | (N=1034) | (N=1887) | (N=2037) |
| Pre-vaccine HAI titre |  |  |  |
| 5 | 29 (2.8%) | 6 (0.3%) | 316 (15.5%) |
| 10 | 44 (4.3%) | 67 (3.6%) | 744 (36.5%) |
| 20 | 64 (6.2%) | 234 (12.4%) | 608 (29.8%) |
| 40 | 158 (15.3%) | 486 (25.8%) | 237 (11.6%) |
| 80 | 188 (18.2%) | 499 (26.4%) | 86 (4.2%) |
| 160 | 193 (18.7%) | 394 (20.9%) | 39 (1.9%) |
| 320 | 209 (20.2%) | 144 (7.6%) | 5 (0.2%) |
| 640 | 97 (9.4%) | 48 (2.5%) | 0 (0%) |
| 1280 | 46 (4.4%) | 7 (0.4%) | 2 (0.1%) |
| 2560 | 6 (0.6%) | 2 (0.1%) | 0 (0%) |
| Sex |  |  |  |
| Female | 852 (82.4%) | 1597 (84.6%) | 1716 (84.2%) |
| Male | 182 (17.6%) | 286 (15.2%) | 321 (15.8%) |
| Other | 0 (0%) | 4 (0.2%) | 0 (0%) |
| Age group (yrs) |  |  |  |
| <30 | 194 (18.8%) | 342 (18.1%) | 352 (17.3%) |
| 30-39 | 303 (29.3%) | 541 (28.7%) | 620 (30.4%) |
| 40-49 | 298 (28.8%) | 537 (28.5%) | 553 (27.1%) |
| 50-59 | 220 (21.3%) | 440 (23.3%) | 472 (23.2%) |
| 60+ | 19 (1.8%) | 27 (1.4%) | 40 (2.0%) |
| Study site |  |  |  |
| Adelaide | 75 (7.3%) | 130 (6.9%) | 165 (8.1%) |
| Brisbane | 138 (13.3%) | 304 (16.1%) | 356 (17.5%) |
| Melbourne | 97 (9.4%) | 244 (12.9%) | 243 (11.9%) |
| Newcastle | 168 (16.2%) | 429 (22.7%) | 443 (21.7%) |
| Perth | 279 (27.0%) | 345 (18.3%) | 426 (20.9%) |
| Sydney | 277 (26.8%) | 435 (23.1%) | 404 (19.8%) |
| Vaccine history  (# in last 5 years) |  |  |  |
| 0 | 131 (12.7%) | 45 (2.4%) | 61 (3.0%) |
| 1 | 99 (9.6%) | 87 (4.6%) | 57 (2.8%) |
| 2 | 79 (7.6%) | 114 (6.0%) | 114 (5.6%) |
| 3 | 52 (5.0%) | 117 (6.2%) | 122 (6.0%) |
| 4 | 98 (9.5%) | 136 (7.2%) | 186 (9.1%) |
| 5 | 575 (55.6%) | 1388 (73.6%) | 1497 (73.5%) |